Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07474792 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 34 → 39 locationsv5
  2. Trial sites expanded: 31 → 34 locationsv4
  3. Trial sites expanded: 27 → 31 locationsv3
  4. Recruitment opened Trial sites expanded: 0 → 27 locations · Start date changed from estimate of Mar 2026 to Mar 19, 2026v2 Show 2 more changesShow less
    • Trial sites expanded: 0 → 27 locations
    • Start date changed from estimate of Mar 2026 to Mar 19, 2026
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-002 in adult participants with moderate-to-severe plaque psoriasis.
Trial Details
NCT Number NCT07474792
Lead Sponsor Oruka Therapeutics, Inc.
Conditions Plaque Psoriasis
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov